本文選題：嵌合抗原受體 + 腫瘤免疫治療��； 參考：《中國(guó)腫瘤生物治療雜志》2017年03期

【摘要】：嵌合抗原受體(chimeric antigen receptor,CAR)是單鏈抗體的可變區(qū)(single-chain variable fragments,scFv)和T細(xì)胞信號(hào)分子的重組融合蛋白,它使T細(xì)胞可以通過(guò)非MHC限制性方式識(shí)別特異性抗原。最近的臨床研究證明,CAR-T細(xì)胞在治療B細(xì)胞腫瘤中取得了顯著效果。但在目前的臨床應(yīng)用中存在諸多限制,尤其是當(dāng)腫瘤抗原在正常組織中表達(dá)時(shí)會(huì)造成脫靶效應(yīng)。本文就靶抗原的選擇、脫靶效應(yīng)及相應(yīng)的預(yù)防策略作一綜述,期望這些策略的實(shí)施,將會(huì)提高CAR-T細(xì)胞治療的安全性及有效性,使更多腫瘤患者從中獲益。
[Abstract]:Chimeric antigen receptor carr) is a variable region single-chain variable fragments scFv) and a recombinant fusion protein of T cell signaling molecules, which enables T cells to recognize specific antigens by non-MHC restriction. Recent clinical studies have demonstrated that CAR-T cells are effective in the treatment of B-cell tumors. However, there are many limitations in clinical application, especially when tumor antigens are expressed in normal tissues. In this paper, the selection of target antigen, miss effect and corresponding preventive strategies are reviewed. It is hoped that the implementation of these strategies will improve the safety and effectiveness of CAR-T cell therapy and benefit more cancer patients.
【作者單位】： 河北醫(yī)科大學(xué)第四醫(yī)院腫瘤科;
【分類號(hào)】：R730.51
，

本文編號(hào)：1830052